For research, professional, and investigational evaluation only. No exosome product is FDA-approved for therapeutic use in humans.
For qualified professionals
A documentation-first evaluation path.
Review current records before discussing availability or logistics. No protocol guidance, dosing claims or implied clinical outcomes.
01 / Identify
Tell us your role.
Share your organization, professional role and the material under evaluation.
02 / Review
Receive the available file set.
We match the request to current quality and traceability records available for that product.
03 / Discuss
Clarify availability.
If the documentation matches your requirements, discuss current availability and logistics.
What we provide
Evidence for evaluation—not clinical direction.
- Lot-specific documents when availableCOA, release criteria and related traceability records.
- Product specificationsReported material attributes with source and method context.
- Clear document statusOriginal report, manufacturer release record or private-label summary.
Documentation available
Start with the records.
Tell us what you are evaluating. We will match the request to the relevant current-batch documentation.